Samsung Biologics (KRX:207940) posted second-quarter net income attributable to shareholders of 430.7 billion won, up 29% from 333.6 billion won a year earlier, according to a Thursday filing with the Korea Exchange.
The South Korean contract development and manufacturing company's sales jumped 30% year over year to 1.321 trillion won from 1.014 trillion won.
Shares of Samsung Biologics rose nearly 2% in recent trade.